CDK10 antibody (N-Term)

Catalog No. ABIN391741

Product Details anti-CDK10 Antibody

Target: CDK10 (Cyclin-Dependent Kinase 10 (CDK10))

Binding Specificity: AA 1-32, N-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CDK10 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Predicted Reactivity: M

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This CDK10 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-32 amino acids from the N-terminal region of human CDK10.

Clone: RB3172

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. IHC-P: 1:50~100

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

References for anti-CDK10 antibody (ABIN391741)

Hong, Zhang, You, Qiu, Giuliano, Cui, Zhang, Cui: "Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study." in: BMC cancer, Vol. 15, pp. 548, (2015) (PubMed).

You, Li, Qin, Zhang, Song, Ran, Gao: "Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report." in: Cellular oncology (Dordrecht), Vol. 38, Issue 6, pp. 485-91, (2015) (PubMed).

Leman, Magheli, Yong, Netto, Hinz, Getzenberg: "Identification of nuclear structural protein alterations associated with seminomas." in: Journal of cellular biochemistry, Vol. 108, Issue 6, pp. 1274-9, (2009) (PubMed).

Iorns, Turner, Elliott, Syed, Garrone, Gasco, Tutt, Crook, Lord, Ashworth: "Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer." in: Cancer cell, Vol. 13, Issue 2, pp. 91-104, (2008) (PubMed).

Target Details for CDK10

Target: CDK10 (Cyclin-Dependent Kinase 10 (CDK10))

Alternative Name: CDK10 (CDK10 Products)

Synonyms: PISSLRE antibody, BC017131 antibody, zgc:110252 antibody, DDBDRAFT_0216532 antibody, DDBDRAFT_0229427 antibody, DDB_0216532 antibody, DDB_0229427 antibody, cdc2rk antibody, NV16107 antibody, cyclin dependent kinase 10 antibody, cyclin-dependent kinase 10 antibody, CDK family protein kinase antibody, hypothetical protein antibody, cyclin-dependent kinase 10 L homeolog antibody, CDK10 antibody, Cdk10 antibody, cdk10 antibody, LOC5566134 antibody, cdk10.L antibody

Background: CDK10 belongs to the CDK subfamily of the Ser/Thr protein kinase family. The CDK subfamily members are highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2, and are known to be essential for cell cycle progression. This kinase has been shown to play a role in cellular proliferation. Its function is limited to cell cycle G2-M phase.

Molecular Weight: 41038

Gene ID: 8558

NCBI Accession: NP_001092003, NP_001153839, NP_443713, NP_443714

UniProt: Q15131